Updated Jul 16, 2026
Lamy Patrick is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market sales: $163K.
Patrick Lamy is a corporate executive known for his role as Senior Vice President of Commercial Strategy at Akero Therapeutics, Inc. He has been involved in several SEC filings related to his position at the company.
| Role | Insider |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2025-12-09 | AKRO | Akero Therapeutics, Inc. | D — Derivative transaction | 26.8K | — | |
| 2025-12-09 | AKRO | Akero Therapeutics, Inc. | D — Derivative transaction | 3.1K | — | |
| 2025-07-01 | AKRO | Akero Therapeutics, Inc. | S — Open-market sale | 2.0K | $52.88 | $106K |
| 2025-06-30 | AKRO | Akero Therapeutics, Inc. | A — Grant or award | 193 | $23.87 | $5K |
| 2024-12-18 | AKRO | Akero Therapeutics, Inc. | S — Open-market sale [10b5-1] | 1.0K | $29.13 | $29K |
| 2024-12-18 | AKRO | Akero Therapeutics, Inc. | A — Grant or award [10b5-1] | 17.4K | $0.00 | |
| 2024-12-12 | AKRO | Akero Therapeutics, Inc. | S — Open-market sale | 925 | $30.79 | $28K |
Patrick Lamy is a corporate executive known for his role as Senior Vice President of Commercial Strategy at Akero Therapeutics, Inc. He has been involved in several SEC filings related to his position at the company.…
Recorded transactions: 0 open-market purchases () and 3 open-market sales ($163K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Lamy Patrick profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.